

# Welcome to TRUMENBA



**Order**



**Stock**



**Vaccinate\***



**Complete  
the series**

## Guidance on implementing a serogroup B meningococcal disease (MenB) vaccination protocol with TRUMENBA

\*TRUMENBA is approved as a 2- or 3-dose schedule.<sup>1</sup>

### INDICATION

- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age

### SELECTED SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
- Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
- Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* serogroup B even if they develop antibodies following vaccination with Trumenba

Please [click here](#) for full Important Safety Information and [click here](#) for full Prescribing Information.

 **Trumenba**<sup>®</sup>  
Meningococcal Group B Vaccine

# Order



## Place an initial order for both VFC and private orders

There are 3 ways to order **TRUMENBA**:

1. Order, track, and pay online at [PfizerPrime.com](https://PfizerPrime.com)
2. Order by phone at 1-800-666-7248
3. Order from your wholesaler or from your Pfizer representative

Type	Code	Quantity
NDC	0005-0100-05	Five pack
NDC	0005-0100-10	Ten pack



**TIP:** Consider ordering the same amount of **TRUMENBA** as the MenACWY vaccine.

**IMPORTANT:** Make sure TRUMENBA is listed as your default MenB vaccination in your EHR (see EHR setup: steps to activate MenB immunizations on next page).

EHR=electronic health record; MenACWY=meningococcal serogroups A, C, W, Y vaccine; VFC=Vaccines for Children.

### SELECTED SAFETY INFORMATION

- > Vaccination with Trumenba may not protect all vaccine recipients against *N meningitidis* serogroup B infections
- > Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting

Please [click here](#) for full Important Safety Information and [click here](#) for full Prescribing Information.

## EHR setup: steps to activate MenB immunizations

- 1 Ensure the product is built within the EHR**  
(pharmacy EHR team)
- 2 Configure order as an immunization**  
(EHR IT analyst)
- 3 Create records to allow ordering and administration documentation of immunization**  
(EHR IT analyst)
- 4 Streamline ordering process by marking immunization as a favorite or as a preference**  
(EHR IT analyst)

---

### Pediatric CPT codes

Code	Description
90460	Administration of a vaccine with counseling; first vaccine/component
90461	Administration of a vaccine with counseling; each additional vaccine/component
90471	Administration of a vaccine without counseling

CPT=current procedural terminology.

### SELECTED SAFETY INFORMATION

➤ In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)

Please [click here](#) for full Important Safety Information and [click here](#) for full Prescribing Information.

# Stock

---



## Store TRUMENBA in the refrigerator<sup>1</sup>

- Keep TRUMENBA at temperatures between 2°C and 8°C (36°F and 46°F)
- Store TRUMENBA syringes lying flat on the shelf



**TIP:** Keep enough TRUMENBA in stock to avoid missed opportunities to vaccinate.



**IMPORTANT:** Make sure everyone on your staff is aware of your TRUMENBA implementation. On the first day of your implementation, consider placing a note in the refrigerator where vaccines are stored.


## SELECTED SAFETY INFORMATION

- Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness have not been established in pregnant women

Please [click here](#) for Important Safety Information and [click here](#) for full Prescribing Information.

# Vaccinate\*

---



## How to use TRUMENBA<sup>1</sup>

- Before using TRUMENBA, shake syringe vigorously to make sure it is mixed—it should be completely white. TRUMENBA should be given as an intramuscular injection
- Use a sterile needle attached to the prefilled syringe
- Do not mix TRUMENBA with any other vaccine in the same syringe



**TIP:** If you are switching from a different MenB vaccine, ensure your immunization processes, resources, and plans are updated to incorporate TRUMENBA.

**IMPORTANT:** If you have MenB standing orders in place, ensure they now include TRUMENBA. Similarly, patient education materials should be updated to avoid any confusion.

\*TRUMENBA is approved as a 2- or 3-dose schedule.<sup>1</sup>

## SELECTED SAFETY INFORMATION

- Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* serogroup B even if they develop antibodies following vaccination with Trumenba

Please [click here](#) for Important Safety Information and [click here](#) for full Prescribing Information.

# Complete the series

---



## As patients receive a first dose:

- Make a strong recommendation to complete the series
- Prompt enrollment in the **REMEMBER TRUMENBA** text reminder program and schedule their next dose before they leave

## If patients are due or overdue for **TRUMENBA**:

- Run a list to identify patients and engage them with reminder or recall communications
- Use here-and-now patient visits (eg, flu vaccinations, sports physicals, etc.) as opportunities to discuss initializing or completing **TRUMENBA**



**TIP:** If you are switching from a different MenB vaccine, remember that MenB vaccines are not interchangeable, and the same product must be used for all doses.<sup>2</sup>

**IMPORTANT:** Consider engaging patients who previously started any MenB series in reminder recall to help them complete the full series.

## SELECTED SAFETY INFORMATION

- Vaccination with Trumenba may not protect all vaccine recipients against *N meningitidis* serogroup B infections
- Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting

Please [click here](#) for Important Safety Information and [click here](#) for full Prescribing Information.



## Help set yourself up for success by identifying:

- A **TRUMENBA** implementation champion to lead your effort
- A start date to begin implementing **TRUMENBA**
- A check-in with your representative to evaluate progress



### SELECTED SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
- Some individuals with altered immunocompetence may have reduced immune responses to Trumenba

Please [click here](#) for Important Safety Information and [click here](#) for full Prescribing Information.

To order resources that can support your vaccination efforts including patient education materials and series completion resources, talk to your Pfizer representative or call the Pfizer Vaccines Support Team at 844-439-2571.



Pfizer has additional resources to help educate your patients about MenB. Visit [www.trumenbaresources.com](http://www.trumenbaresources.com) to find out more.

## INDICATION

- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age

## IMPORTANT SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
- Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
- Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by *Neisseria meningitidis* serogroup B even if they develop antibodies following vaccination with Trumenba
- Vaccination with Trumenba may not protect all vaccine recipients against *N meningitidis* serogroup B infections
- Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
- In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%)
- Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness have not been established in pregnant women

Please [click here](#) for full Prescribing Information.

**References:** 1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 2. Patton M, Stephens D, Moore K, MacNeil J. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine—Advisory Committee on Immunization Practices, 2016. *MMWR Morb Mortal Wkly Rep.* 2017;66(19):509-513.

